Programmable bacteria induce durable tumor regression and systemic antitumor immunity

Posted by: | July 10, 2019 | Comments

Map of plasmids used in this study


Synthetic biology is driving a new era of medicine through the genetic programming of living cells1,2. This transformative approach allows for the creation of engineered systems that intelligently sense and respond to diverse environments, ultimately adding specificity and efficacy that extends beyond the capabilities of molecular-based therapeutics3,4,5,6. One particular area of focus has been the engineering of bacteria as therapeutic delivery systems to selectively release therapeutic payloads in vivo7,8,9,10,11. Here we engineered a non-pathogenic Escherichia coli strain to specifically lyse within the tumor microenvironment and release an encoded nanobody antagonist of CD47 (CD47nb)12, an anti-phagocytic receptor that is commonly overexpressed in several human cancer types13,14.

Read more at: Nature Medicine

Sreyan Chowdhury, Samuel Castro, Courtney Coker, Taylor E. Hinchliffe, Nicholas Arpaia & Tal Danino. Nature Medicine. 03 July 2019.

Stay up-to-date!
Email Address *
First Name
Last Name

* indicates required
Privacy Policy

Terms & Conditions | Privacy Policy | © 2020 The Translational Microbiome Research Forum